Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1378/chest.82.1_supplement.22s | DOI Listing |
Cureus
December 2024
Department of Diagnostic Pathology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, JPN.
Pleomorphic adenoma of the trachea is a rare benign tumor, often challenging to diagnose due to nonspecific symptoms. We report a case of a 72-year-old female with a 10-year history of presumed bronchial asthma, presenting with persistent dyspnea. Preoperative assessment for breast cancer surgery revealed severe obstructive ventilatory impairment.
View Article and Find Full Text PDFJ Surg Case Rep
January 2025
Section of Cardiothoracic Surgery, Aga Khan University Hospital, 74800, Karachi, Pakistan.
Endobronchial lipoma is an extremely rare benign tumor, accounting for 0.1%-0.5% of all lung tumors.
View Article and Find Full Text PDFRespir Med Case Rep
December 2024
Department of Pulmonology & Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Prof. dr. Chairuddin P. Lubis Universitas Sumatera Utara Hospital, Jl. Dr. Mansur No. 5, Medan, 20155, Indonesia.
Mediastinal tuberculosis poses significant diagnostic challenges due to its nonspecific clinical and radiological features, particularly in high TB incidence regions like Indonesia. Here, we present the case of A 17-year-old male, initially diagnosed with a mediastinal tumor, was later confirmed to have mediastinal tuberculosis (TB). Despite normal lab results, imaging revealed a right parahilar mass.
View Article and Find Full Text PDFJ Ethnopharmacol
January 2025
Pharmacy School, Shihezi University, Xinjiang, 832000, China; Xinjiang Key Laboratory of Uygur Medicine, Xinjiang Institute of Materia Medica, Xinjiang, 830000, China. Electronic address:
Ethnopharmacological Relevance: Regan Saibisitan (RGS) is a classic prescription used to treat cough, pneumonia, and other respiratory infections in Uygur medicine. It is a granule composed of 12 kinds of medicinal materials. However, the mechanism by which RGS regulates lung disease remains unclear.
View Article and Find Full Text PDFCrit Rev Toxicol
January 2025
Syngenta, Bracknell, United Kingdom.
While progress has been made in recent years, there are still no suitable and accepted , or models that can be used to accurately predict whether a chemical substance has the intrinsic property to cause immune-mediated chemical respiratory allergy, typically manifested as allergic asthma or allergic rhinitis which represents a severe health hazard. Regulatory authorities have relied primarily on clinical evidence (case reports, clinical databases, worker exposure studies) to classify substances as respiratory sensitizers, but this evidence can lack a proven immunological mechanism which is necessary to identify substances which can cause life-long sensitization and clinically relevant allergic symptoms in the respiratory tract in an exposed population (such respiratory allergens may be considered as "true" sensitizers, in analogy to the definition of skin sensitization, and in contrast to respiratory irritants). In light of this, the European Center for Ecotoxicology and Toxicology of Chemicals convened a Task Force to evaluate the types of clinical methods and data sources and the implications of relying on such data for regulatory decision making from a scientific perspective.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!